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Alpha-1-acid glycoprotein (AGP), an acute phase
protein in serum assayed by single radial immunodiffusion using a commercially available kit, was
found to significantly increase in mice infected
with influenza A and B viruses. Experiments were
run to determine the rate of increase of serum
AGP and its relation to other influenza disease
parameters, including lung consolidation, development of lung virus titres, decline in arterial oxygen saturation (SaO2), histopathological changes
in the lung, and death of the animal. Maximal AGP
levels occurred by day 3 in the animals, at about
the same time lung virus titres reached their peak
and inflammatory effects were evident in the
lung. Serum levels of AGP were then compared
with other disease parameters in the evaluation of
the anti-influenza A and B virus efficacy of
oseltamivir and ribavirin in mice. Treatment was
by oral gavage twice daily for 5 days, beginning
4 h before virus exposure using doses of 100, 10,
and 1 mg/kg per day of oseltamivir and 75 mg/kg
per day of ribavirin. Against the influenza A infection, significant inhibition of death, SaO2 decline,
and lung consolidation was seen at all doses of

each compound; day-6 AGP levels were reduced in
a dose-responsive manner. Lung virus titres were
lessened at this time, but to a significant degree
only at the high dose of oseltamivir and by ribavirin. The influenza B virus infection, which
appeared more severe than the influenza A infection, was also significantly inhibited by both compounds, but to a lesser extent. The serum AGP levels were again lessened by therapy with both
compounds. The influence of challenge dose of
influenza A virus on AGP level and on the antiviral
activity of 20 mg/kg per day of oseltamivir, administered by oral gavage, was determined in mice.
The AGP level was in proportion to the viral challenge dose; oseltamivir significantly inhibited AGP
levels and all other disease parameters regardless
of size of viral inoculum. These data indicate
murine AGP levels to be markedly stimulated by
infection with influenza A and B viruses, and the
level of the protein to be an additional measure of
antiviral efficacy.
Keywords: alpha-1-acid glycoprotein, influenza
virus, antiviral, oseltamivir

Introduction
Alpha-1-acid glycoprotein (AGP) is one of the major acute
phase proteins in serum produced by macrophages, liver
cells, and polymorphonuclear lymphocytes (Schmid, 1975).
The material increases dramatically in mammalian systems
when inflammation, pregnancy, or cancer occurs (Bacchus,
1975; Schmid, 1975). The protein has also been referred to
as an immunosuppressive acidic protein, since it displays
suppressive activity against various immune responses in
vitro and in vivo (Tamura et al., 1981; Aso et al., 1992).
Virus infections have been shown to cause an increase in
the serum concentration of two acute phase reactants (Creactive protein and amyloid A protein) (Saloken & Vaheri,
1981; Griffin et al., 1983; Whicher et al., 1985), suggesting
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that AGP may respond similarly. Wong et al. (1989) have
subsequently reported that acute influenza A virus infections in mice result in a moderate (up to 48%) increase in
this protein, finding a correlation with AGP serum level
and lung consolidation.
As a follow-up to that latter report, it was thought that
the increased AGP seen in the serum of influenza virus
infected mice may be useful as an additional parameter for
use in the evaluation of the efficacy of potential antiviral
drugs. Current methods of assessing influenza disease progression are not always accurate. The assignment of a score
for lung consolidation is quite subjective; lung weight
increase is a general assessment that indicates increased
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Figure 1. Comparison of development of serum alpha-1-acid glycoprotein levels with disease parameters in
mice infected with influenza A/Shangdong/09/93 (H3N2) virus

(a) Arterial oxygen saturation, SaO2. (b) Lung scores. (c) Lung weights. (d) Lung virus titres.
AGP, alpha-1-acid glycoprotein.

fluid in the lungs, but does not reflect the condition of the
lung tissue. Histopathological analysis is cumbersome and
difficult to quantitate. Only arterial oxygen saturation
(SaO2), as measured by pulse oximeter, has provided a
quantitative and reproducible assessment of lung condition,
although it can only be used in albino mice, since poor light
transmission through the vascular bed occurs in pigmented
animals (Sidwell et al., 1992). Also, SaO2 decline is less
apparent in animals infected with low viral challenge doses.
Thus, measurement of serum AGP levels may provide an
additional quantitative assessment of alleviation of tissue
injury in infected, drug-treated animals.
A kit for the quantitation of this protein using radial
immunodiffusion has recently become commercially
available (Saikin Kagaku Institute, Sendai, Japan), providing a means of readily determining serum levels on a standardized basis. Since the studies by Wong et al. (1989)
utilized rocket immunoelectrophoresis using AGP antiserum prepared in their laboratory, it was thought important to repeat those studies, using the immunodiffusion
kit, in mice infected with both influenza A and B viruses.
Once it had become established when the protein
achieved maximal levels in relation to lung consolidation,
lung virus titres, SaO2 decline, and occurrence of death,
experiments were run comparing serum AGP levels to
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these other disease parameters in mice treated with the
influenza neuraminidase inhibitor oseltamivir, which has
been shown to be markedly effective in the treatment of
murine influenza infections (Mendel et al., 1998; Sidwell et
al., 1998), or with the broad spectrum antiviral ribavirin
(Sidwell et al., 1972).

Materials and methods
Animals
Female specific pathogen-free 18-21 g BALB/c mice were
obtained from B & K International (Fremont, Calif.,
USA). Housing and care of the animals were as described
previously (Sidwell et al., 1992).

Viruses
Influenza A/Shangdong/09/93 (H3N2) was provided by
H Regnery (Centers for Disease Control and Prevention,
Atlanta, Ga., USA). It was passaged seven times through
mice and then a pool was prepared in MDCK cells.
Influenza B/Hong Kong/05/72 virus was obtained from
the American Type Culture Collection (Manassas, Va.,
USA). It was passaged a single time through mice and used
as a mouse lung homogenate. Both virus pools were stored
at –80°C and pretitrated in mice before use in this study.
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Figure 2. Comparison of development of serum alpha-1-acid glycoprotein levels with disease parameters in
mice infected with influenza B/Hong Kong/05/72 virus

(a) Arterial oxygen saturation, SaO2. (b) Lung scores. (c) Lung weights. (d) Lung virus titres.
AGP, alpha-1-acid glycoprotein.

Alpha-1-acid glycoprotein determination
Serum was assayed by single radial immunodiffusion using
a kit from Saikin Kagaku Institute (Sendai, Japan). The kits
contained test plates with 10 wells each. Standard solutions
of mouse AGP at 1000 µg/ml and 250 µg/ml were included in the kits as controls.

SaO2 determination
An Ohmeda Biox 3740 pulse oximeter (Ohmeda,
Louisville, OH, USA) was used to measure percentage
SaO2 in the mice. The human ear probe attachment was
placed on the thigh of the animal, with readings made after
a 20 s stabilization time on each animal as previously
described (Sidwell et al., 1992).

Lung virus titre determination
Each lung was homogenized to a 10% w/v suspension in
minimum essential medium supplemented with 0.18%
NaHCO3 and 50 µg gentamicin/ml. Each homogenate was
assayed in triplicate in MDCK cells in 96-well microplates
with viral cytopathic effect determined visually as an endpoint, as described previously (Sidwell et al., 1985).

Test compound
Oseltamivir was provided by Dr Chung Kim of Gilead
Sciences (Foster City, Calif., USA). Ribavirin was obtained
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from ICN Pharmaceuticals (Costa Mesa, Calif., USA). Each
was dissolved in sterile saline for use in these experiments.

Statistical analysis
Increases in survivor numbers were evaluated by χ2 analysis
with Yates’ correction for small sample size. Differences in
mean day to death, SaO2 levels, virus titres, and AGP levels were analysed by t test. Wilcoxon ranked sum analysis
was used for comparing differences in mean lung scores.

Experiment design: comparison of serum alpha1-acid glycoprotein to influenza disease
parameters
Experiments were done in mice infected with influenza A
and B viruses to determine the rate of development of
serum AGP, and to compare this rate with the development
of the infection in the mice. In each experiment, a group of
50 mice were infected intranasally as described previously
(Sidwell et al., 1998). For influenza A/Shangdong, this was
a virus dose of 105.5 50% cell culture infectious doses
(CCID50)/ml; for influenza B/Hong Kong, the virus dose
was 107.0 CCID50/ml. Five mice were killed on days 1, 3, 6,
9, 12 and 15 after virus exposure. The serum was assayed at
each time point for AGP, and their lungs were assigned a
consolidation score ranging from 0 (normal lung) to 4
(maximal plum coloration), weighed and assayed for virus
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Table 1. Effect of orally administered oseltamivir or ribavirin on an influenza A virus infection in mice:
comparison of serum alpha-1-acid glycoprotein with other disease parameters

Treatment
Oseltamivir

Ribavirin
H2O

Dose
Survival
(mg/kg/day) /total
100
10
1
75
–

10/10‡
9/10‡
3/10*
10/10‡
0/20

MDD§
(days ±SD)
>21.0
10.0
12.2
>21.0
10.5

±0.0‡
±0.0
±3.3*
±0.0‡
±2.4

Day 6 mean data
Day 10 SaO2∫ Lung score Lung weight
Lung virus titre AGP¶ titre
(% ±SD)
±SD
(mg ±SD)
(log10/g ±SD)
(µg/ml ±SD)
86.5
85.5
84.7
88.6
77.7

±1.6‡
±3.8‡
±5.5‡
±2.6‡
±4.7

1.3
1.4
2.6
0.9
3.0

±1.3*
±1.3*
±0.4
±1.3†
±0.4

180
216
214
180
236

±26*
±39
±47
±52
±34

5.0
5.8
5.3
4.3
6.0

±0.3*
±0.4
±0.5
±0.3†
±0.5

104
124
164
83
188

±28†
±47*
±39
±26†
±17

Oseltamivir was administered twice daily ×5, beginning 4 h before virus exposure. Toxicity controls treated with all doses of oseltamivir all survived and gained 1.9–2.2 g during therapy; those treated with ribavirin all survived and gained 0.8 g during the same period. Normal controls:
day 10 mean SaO2%: 89.0 ±3.2; mean lung score: 0.0; mean lung weight: 114.0 ±11.0 mg; mean alpha-1-acid glycoprotein titre: 72.0 ±6.5.
*P<0.05, †P<0.01, ‡P<0.001 compared with H2O-treated controls.
§Mean day to death of mice dying before day 21.
∫Arterial oxygen saturation.
¶Alpha-1-acid glycoprotein measured by single radial immunodiffusion.

titre. A portion of each lung was placed in formalin, sections made, stained with haematoxylin and eosin, and
examined microscopically for abnormalities. A group of
10 infected mice were held the duration of the study for
occurrence of death, and SaO2 values determined daily
from days 3 to 11, during the time period when SaO2
decline usually occurs (Sidwell et al., 1992).
As controls, 35 uninfected mice were run in parallel in
each experiment; five were killed at the same time as the
infected mice and the same parameters described above
determined to provide baseline data. The remaining five
mice were assayed for SaO2 levels in parallel with the
infected animals.

Experiment design: antiviral studies
Mice infected with a LD100 dose of influenza A (105.0
CCID50/ml) or B (107.0 CCID50/ml) virus were treated by
oral gavage with oseltamivir at doses of 100, 10 or 1 mg/kg
per day or with 75 mg/kg per day of ribavirin. Fifteen mice
were used in each dosage group, with 30 infected animals
treated in parallel with sterile H2O. Ten animals in each
drug-treated group and 20 H2O-treated controls were
assayed from days 3 to 11 for levels of SaO2; deaths were
noted daily for 21 days. The remaining animals were killed
on day 6 and their lungs assigned a consolidation score,
weighed and assayed for virus titre. Serum taken at this
time was analysed for levels of AGP. Three uninfected mice
were treated in parallel with each drug dosage to serve as
toxicity controls. They were weighed immediately before
the initial treatment and again 18 h after final treatment
and observed for 21 days.
An additional experiment was done in which mice were
challenged with four varying log10 doses of influenza A
virus, the highest dosage being 105.75 CCID50 per ml.
Oseltamivir in a dose of 20 mg/kg per day was administered to each group of mice twice daily for 5 days, beginning 4 h before virus exposure. Eight infected drug-treated
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mice and eight H2O-treated animals in each group were
observed for death for 21 days, and SaO2 values determined
on days 3–11. Four additional drug- or H2O-treated mice
in each group were killed on day 6 and their lungs removed,
assigned a consolidation score, weighed and assayed for
virus titre. Their serum was also taken on day 6 and assayed
for AGP levels.

Results
Comparison of serum alpha-1-acid glycoprotein
levels to influenza disease parameters
The results of the experiment using influenza A virus
infected mice are shown in Figure 1. This influenza A
infection was lethal to 90% of the mice, their mean day to
death being 6.5 days. The mean (±SD) AGP level in uninfected mice was 74 (±16) µg/ml; in the infected mice, the
protein rose rapidly to a maximum mean of 725 (±25)
µg/ml by day 3, then gradually declined to near-normal
levels by day 11. The SaO2 levels (Figure 1a) began to significantly decline on day 6, reaching minimum levels of
approximately 76% by day 9. Lung consolidation, as seen
by lung scores of 1 or more, and mean weight increases of
nearly double the normal weight, were also seen by day 3,
although reached maximal consolidation by day 5 (Figures
1b, c). Lung virus titres rose dramatically to maximal levels
of approximately 108 CCID50/g by day 1 (Figure 1d).
The data obtained using influenza B virus-infected mice
are seen in Figure 2. This infection was less lethal to the
mice, killing only 10%, but the AGP levels rose at about the
same rate as seen in the influenza A virus-infected mice,
reaching a mean maximum level of 565 (±75) µg/ml by
day 3, gradually declining thereafter (Figure 2); with this
less lethal infection, the SaO2 decline was less pronounced,
but occurred beginning on day 6 (Figure 2a). Lung consolidation, as shown by increased lung scores and lung weights,
was significantly increased in the mice by day 3, correlating
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Table 2. Effect of orally administered oseltamivir or ribavirin on an influenza B virus infection in mice:
comparison of serum alpha-1-acid glycoprotein with other disease parameters

Treatment
Oseltamivir

Ribavirin
H2O

Dose
(mg/kg/day)

Survival
/total

100
10
1
75
–

8/9‡
2/10
3/10*
7/9†
0/17

MDD§
(days ±SD)
13.0
9.4
7.3
8.0
6.0

±0.0‡
±6.8*
±2.8*
±7.0
±1.1

Day 5 mean data
Day 10 SaO2∫ Lung score Lung weight
Lung virus titre AGP¶ titre
(% ±SD)
±SD
(mg ±SD)
(log10/g ±SD)
(µg/ml ±SD)
85.4
77.7
79.5
84.1
75.0

±2.4‡
±4.4*
±5.8†
±4.1‡
±0.0

0.5
1.0
2.1
0.8
2.8

±0.4†
±0.0†
±0.4
±0.2†
±1.0

180
164
250
152
284

±17†
±9†
±43
±4†
±60

3.5
3.9
3.6
3.1
3.9

±1.2
±0.5
±0.1
±0.5*
±0.5

311
321
290
415
512

±27*
±54*
±26*
±109
±139

Oseltamivir was administered twice daily ×5, beginning 4 h before virus exposure.
*P<0.05, †P<0.01, ‡P<0.001 compared with H2O-treated controls.
§Mean day to death of mice dying before day 21.
∫Arterial oxygen saturation
¶Alpha-1-acid glycoprotein measured by single radial immunodiffusion.

well with AGP levels (Figures 2b, c). High lung virus titres
were seen in the mice with the maximal titres seen at about
the same time as the AGP levels (Figure 2d).
Histological analysis of lungs from each infected group
revealed a typical pattern of influenza virus induced lung
inflammation. On day 1, thickening of alveolar walls accompanied by about 10% of the bronchial epithelial cells having
pyknotic and karyorrhectic nuclei indicative of necrosis was
seen. This occurred on the same day lung virus titres were at
their peak and AGP levels were significantly increasing. By
day 3, the same anomalies were seen to a greater extent
accompanied by macrophages, lymphocytes and neutrophils
in the alveolar spaces. As the infection progressed in the animal, changes in the lung indicating interstitial pneumonia
became more pronounced. Importantly, the initial damage to
lung tissue indicative of inflammation occurred when the
AGP values were at their maximum.

Antiviral experiments
The results of the experiment using oral gavage administered
oseltamivir or ribavirin on an influenza A virus infection in
mice are summarized in Table 1. As expected, based on earlier studies done with these compounds, significant antiviral
efficacy was observed using each, with the effects of
oseltamivir being dose responsive by all parameters. The
serum AGP levels were significantly reduced by treatment
with all dosages of oseltamivir, and by ribavirin therapy. It is
noted that the day 6 AGP levels seen in the H2O-treated
mice were similar to that observed earlier (Figure 1). Neither
compound exhibited signs of toxicity in the uninfected controls, although the weight gain during ribavirin therapy was
less than that observed with any dose of oseltamivir.
The antiviral study with influenza B virus shown in
Table 2 used a higher viral challenge dose than that used in
the initial kinetics experiment with this virus, such that all
the H2O-treated animals died with a relatively early mean
day to death of 6.0 days. Oseltamivir therapy significantly
inhibited the infection using all disease parameters, the effi-
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cacy being most apparent at the 100 and 10 mg/kg per day
doses. The serum AGP levels were significantly lessened at
all doses. Ribavirin was also inhibitory to this infection, as
confirmed by all disease parameters. The mean serum AGP
level was approximately 100 µg/ml lower than the H2Otreated controls, but this reduction was not statistically significant.
An experiment was run to determine the influence of an
influenza A viral challenge dose on the antiviral efficacy of
oseltamivir (Table 3). Again, the effects of the disease
parameters were compared with the serum AGP levels. In
this study, a single dose, 20 mg/kg per day, of oseltamivir was
used. As expected, the disease induced in the mice increased
with viral challenge dose, the highest (10–2 dilution, 105.75
CCID50/ml) challenge being 100% lethal to the mice, with
the animals having a mean day to death of only 4.9 (±0.7)
days. The 10–4 viral challenge was only lethal to 50% of the
animals, and the 10–5 viral challenge did not kill the mice,
although lung consolidation, high virus titres in the lungs,
and high AGP levels together with mild SaO2 decline
occurred. Therapy with 20 mg/kg per day of oseltamivir was
significantly inhibitory at all viral challenge doses. This
antiviral effect was also seen in significantly lowered serum
AGP levels in all groups.

Discussion
These data show that mouse serum levels of AGP, as determined by a commercially available kit, increase significantly
following infection with either influenza A or B. These
results confirm and extend the findings of Wong et al.
(1989). The data clearly show that a rise in AGP occurs in
mice infected with either influenza A or B viruses, and that
the degree of AGP elevation appears dependent on viral
challenge dose, and thus is a reflection of tissue damage due
to the virus infection.
A comparison of influenza disease parameters and serum
AGP levels indicate the closest correlation to exist between
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Table 3. Influence of influenza A virus challenge dose on the efficacy of orally administered oseltamivir:
comparison of serum AGP with other disease parameters

Treatment
Oseltamivir
H2O
Oseltamivir
H2O
Oseltamivir
H2O
Oseltamivir
H2O

Virus
challenge
(CCID50/ml)
105.75
104.75
103.75
102.75

Survival
/total
8/8‡
0/8
8/8‡
0/8
8/8*
4/8
8/8
8/8

MDD§
(days ±SD)
>21.0
4.9
>21.0
7.8
>21.0
8.0
>21.0
>21.0

±0.0‡
±0.7
±0.0‡
±3.9
±0.0‡
±2.4
±0.0
±0.0

Day 11 SaO2∫
(% ±SD)
88.1
75.0
87.1
76.0
87.1
80.5
86.9
86.8

±1.8‡
±0.0
±1.2‡
±2.8
±1.5†
±6.0
±1.6
±2.0

Day 6 mean data
Lung score Lung weight Lung virus titre AGP titre¶
±SD
(mg ±SD)
(log10/g ±SD)
(µg/ml ±SD)
0.4
4.0
0.1
3.5
0.0
2.8
0.0
1.1

±0.8‡
±0.0
±0.2‡
±0.6
±0.0‡
±0.9
±0.0†
±0.5

200
460
165
435
165
360
152
248

±22‡
±0.0
±19‡
±50
±24‡
±58
±10‡
±17

5.3
7.3
5.1
6.8
5.3
6.1
5.1
6.6

±0.5‡
±0.0
±0.5†
±0.5
±0.5*
±0.4
±0.4†
±0.6

223
450
130
435
121
361
110
384

±29‡
±0
±63‡
±19
±41†
±107
±29‡
±24

Oseltamivir was administered orally at 20 mg/kg per day, twice daily ×5, beginning 4 h before virus exposure.
*P<0.05, †P<0.01, ‡P<0.001 compared with appropriate H2O-treated controls.
§Mean day to death of mice dying before day 21.
∫Arterial oxygen saturation.
¶Alpha-1-acid glycoprotein measured by single radial immunodiffusion.

lung virus titres, concomitant lung inflammation, and the
protein levels. Since AGP is an acute phase protein, which
has previously been shown to respond to inflammation
(McGregor et al., 1987), such correlation would be expected.
The macrophage is most commonly associated with initiating the cascade of events occurring in the acute phase
response (Baumann & Gouldie, 1994), and these cells were
seen in abundance by day 3, when the AGP levels reached
maximal levels.
A primary objective in conducting these experiments was
to determine if AGP levels could be used as an additional
parameter for evaluating the reduction of viral-induced lung
tissue damage by potential antiviral drugs in the mouse
model. With both influenza A and B, the levels of this protein were reduced by antiviral therapy and correlated well
with other influenza disease parameters. Therapy with both
oseltamivir, a selective inhibitor of influenza virus neuraminidase (Mendel et al., 1998) and ribavirin, whose
triphosphate inhibits influenza virus RNA polymerase
(Eriksson et al., 1977) and more generally blocks DNA synthesis via inhibition of IMP dehydrogenase (Streeter et al.,
1973, Drabikowski et al., 1979) inhibited the elevation of
serum AGP in the infected animals. It was noted, however,
that this inhibition was less in the influenza B virus-infected
mice than in those infected with influenza A virus. This lesser effect may have been a reflection of the viral challenge,
since the influenza B virus-infected mice had a mean day to
death of 6.0 days compared with 10.5 days in the influenza A
virus-infected mice.
In the antiviral experiment with influenza A the serum
AGP levels, while elevated, were not at the maximal levels
seen in Figure 1. This was primarily due to the time (day) on
which the animals were sacrificed in the antiviral experiment,
which was after the maximal levels occurred in the kinetic
experiment. This time was selected in order to obtain greater
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lung consolidation and more SaO2 decline. In the influenza
B virus antiviral experiment, the day 5 AGP levels were higher than those seen in the initial kinetics study. This was presumably due to the higher virus challenge dose used in the
antiviral study. Although an earlier time of assay would be
preferable for measure of serum AGP, if lung parameters are
also to be evaluated, then the day 5 time of sacrifice would be
recommended in future studies since at this latter time all
parameters were significantly elevated.
These experiments indicate that measurement of serum
AGP levels may be used to monitor anti-influenza therapy in
the murine model, and may be of particular value when viral
challenge doses are relatively low, resulting in low lethality in
the mouse. This was especially illustrated in the present
study, in which mice were challenged with varying concentrations of virus.
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